Syngene International Limited Stock: price and insider trades · India
No insider purchase over the last 90 days. The latest, by Nippon India Mutual Fund, was filed 26 May 2026.
Syngene International Limited: what insiders have been doing
This page follows insider dealings at Syngene International Limited as filed with SEBI (PIT + SAST), a company from the Health Care sector. In the past year (18 October 2025 to 18 October 2026), 3 filings came from 3 insiders.
Both sides are active: 2 purchases and 1 sale, from 2 insiders and 1 insider respectively. The amount is not disclosed for 3 filings. Unlike grants, an open-market purchase is paid for by the insider, at the market price.
The last insider purchase was made public on 26 May 2026, 166 days ago. Publication is fast: at least half of the trades appear on SEBI (PIT + SAST) on the same day. The shorter that gap, the sooner other investors can see what insiders have done.
Across the 1,890 companies tracked on its exchange, the median is 4 filings; at 3 filings, this issuer sits below that mark. Over the whole record (from 2021), the tally stands at 2 purchases and 235 sales.
In the same sector, recent insider purchases at Anixa Biosciences Inc and Vivos Inc also feature in our signals. This summary is built from SEBI (PIT + SAST) disclosures alone and does not predict where the share price will go.
Who traded when
BuySaleSince the insiders bought
- -16.1%Entry ₹460.15 · Close 16 Oct 2026 ₹386.10
- -16.1%Entry ₹460.15 · Close 16 Oct 2026 ₹386.10
Entry is the close on the day after publication, the first price a reader could act on. Prices in the listing currency. Past moves are not a forecast.
Analyst consensus: bullish or bearish?
Analysts rate Syngene International Limited Buy (bullish), based on 8 analysts. Average price target: ₹501.88.
This score ranks the purchase within its own market. A position size is suggested only on the venues of the backtested strategy universe; elsewhere, signals stay on watch. Not investment advice.
Transparent value + quality ranking, distinct from the insider signal.
Financial data
as of FY 2026FY ended March 2026 · cache
- 861,450 shares-MarketSEBI:a99faba6cbabacb97e93d56f7c088fabc01764d5
- 1,600,307 shares-MarketSEBI:c7be27ede67796d8365689557a17ac750096bfa7Canonical exit: 24 Aug 2026 (T+90)
- 993,389 shares-MarketSEBI:b8e0df19990c76a76c6222fb0d234f7c4220a0fdCanonical exit: 24 Aug 2026 (T+90)
- 6,190 shares@ ₹850.593.4% of flowEquity SharesSEBI:28f32d90f272bc48e1acd0c103f332b315149b50
- 27,200 shares@ ₹843.5415.0% of flowEquity SharesSEBI:07b59d7cbaf7e5df0b1622138efe6a04752c8dcc
- 58,390 shares@ ₹859.7332.9% of flowEquity SharesSEBI:150ddcc74ef4d9ad91a4ed8805a8c951acca6556
- 8,000,000 shares@ ₹857.6815.9% of flowEquity SharesSEBI:57e4123aae4c2c8bd0756ffebeb2b288705b2536
- 600 shares@ ₹889.3516.8% of flowEquity SharesSEBI:1fffd8cb3ac46d89ae50730020a666caeed48dd2
- 600 shares@ ₹907.1517.3% of flowEquity SharesSEBI:d779a34d9eeacacd898d60923fa109e203497a8c
- 1,500 shares@ ₹913.1731.4% of flowEquity SharesSEBI:1521b816c33918933d9e133aa466cb70e626c117
- 8,200 shares@ ₹858.225.1% of flowEquity SharesSEBI:52cc72390db10c7178555297839d940341e2e766
- 20,000 shares@ ₹876.0312.6% of flowEquity SharesSEBI:f41d3b0b55768570c70a2924441adad80b16c8ea
- 35,000 shares@ ₹913.648.8% of flowEquity SharesSEBI:b31bc8310cb179c9401e132dcf0a639ca17eac27
- 86,431 shares@ ₹889.9321.1% of flowEquity SharesSEBI:7efa8fcd912c6b25f9fdfc553cee345d982d82a9
- 2,394 shares@ ₹873.59982.7% of flowEquity SharesSEBI:fa07d3858e629c008bf217a11fc9dce1781434d8
- 2,587 shares@ ₹880.002.5% of flowEquity SharesSEBI:db562ede74e7d46192ce8ca9b61041836e21ce3d
- 2,500 shares@ ₹872.002.4% of flowEquity SharesSEBI:8928d04a1aa26994b22662247bbdc230f25e9600
- 5,000 shares@ ₹845.004.6% of flowEquity SharesSEBI:c3600f30be65c285c4b5c158a874d481a124fc8b
- 1,000 shares@ ₹853.990.6% of flowEquity SharesSEBI:56ea5e1ea4dd6b106767491bc07ce72de9810e6c
- 500 shares@ ₹857.080.3% of flowEquity SharesSEBI:fc0dc44b543c2714a82b2ec1189dea7577b080b6
- 5,000 shares@ ₹846.886.7% of flowEquity SharesSEBI:d2a0342a5a0570bcf40156637dbc28879818c073
- 6,400 shares@ ₹850.508.0% of flowEquity SharesSEBI:b36447e9ff1030b4b09ae463ddf61b7fd58e4458
- 7,100 shares@ ₹840.997.7% of flowEquity SharesSEBI:69c2ff203a36d8d2d081d9aced6a80de9e4d0756
- 5,600 shares@ ₹840.994.8% of flowEquity SharesSEBI:b312cd8abb8929f668aab9da434e41e9bdbb5de9
- 5,687 shares@ ₹841.04994.8% of flowEquity SharesSEBI:7e94b8ec24d12a994d7fd2f68f38a4e825f66e20
25 of 367 declarations
About Syngene International Limited
Syngene International Limited is a company focused on research and development in biopharmaceutical solutions. It provides contract research services to pharmaceutical and biotechnology companies.
